Artwork

Konten disediakan oleh IMPACT Medicom. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh IMPACT Medicom atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP1: Introduction to EV

16:05
 
Bagikan
 

Manage episode 361758945 series 2812899
Konten disediakan oleh IMPACT Medicom. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh IMPACT Medicom atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinical trials examining the efficacy and safety of EV for the treatment of urothelial carcinoma.
Our Guests:
We introduce the topic in our first episode with Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC.
Dr. Joel Claveau, a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion.
This podcast episode was sponsored by Seagen Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

  continue reading

68 episode

Artwork
iconBagikan
 
Manage episode 361758945 series 2812899
Konten disediakan oleh IMPACT Medicom. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh IMPACT Medicom atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemotherapy to treatment with novel therapies such as enfortumab vedotin, or EV. We then focus on the key clinical trials examining the efficacy and safety of EV for the treatment of urothelial carcinoma.
Our Guests:
We introduce the topic in our first episode with Dr. Normand Blais, who is a medical oncologist and Director of clinical research in thoracic oncology at the CHUM and adjunct professor at McGill University in Montreal, QC.
Dr. Joel Claveau, a dermatologist specializing in the diagnosis and treatment of Melanoma and Skin Cancers, and an Associate Professor with the Department of Medicine at Laval University guides us through this discussion.
This podcast episode was sponsored by Seagen Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.

  continue reading

68 episode

Tutti gli episodi

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat

Dengarkan acara ini sambil menjelajah
Putar